Stock comparison
IDEXX Laboratories
Viatris
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
VTRS
Viatris
Market cap
$19.39B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | VTRS | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 31F | IDXX |
| Benjamin Graham | 80A | 27F | IDXX |
| Philip Fisher | 75B | 18F | IDXX |
| Peter Lynch | 71B | 7F | IDXX |
| Joel Greenblatt | 83C | 0F | IDXX |
| Charlie Munger | 87A | 26F | IDXX |
| Terry Smith | 84A | 17F | IDXX |
Side-by-side metrics
| Metric | IDXX | VTRS |
|---|---|---|
| Market cap | $44.12B | $19.39B |
| P/E (TTM) | 39.0x | - |
| EV/EBIT | 31.6x | - |
| ROIC (TTM) | 40.66% | 0.16% |
| Gross margin | 62.05% | 34.4% |
| Net margin | 24.63% | -2.04% |
| Revenue CAGR 5y | 7.56% | -5.44% |
| EPS CAGR 5y | 10.79% | -69.69% |
| Debt / Equity | 0.7x | 1.0x |
| Dividend yield | 0.0% | 2.8% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- Revenue CAGR 5y7.56%vs -5.44%+172%
- EPS CAGR 5y10.79%vs -69.69%+115%
- Net margin24.63%vs -2.04%+108%
- ROIC (TTM)40.66%vs 0.16%+100%
VTRS leads on
- P/E (TTM)-vs 39.0x+158%
- EV/EBIT-vs 31.6x+139%
- Dividend yield2.8%vs 0.0%+100%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.